A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.
Leslie Sandberg Orne
Advertisement
Leslie Sandberg Orne is the president and chief executive officer of Trinity Life Sciences.
Articles by Leslie Sandberg Orne
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
2
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
3
AstraZeneca to Announce Deal with Trump Administration: Report
4
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
5
